Limits...
A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.

Hirata M, Kanai Y, Naka S, Yoshimoto M, Kagawa S, Matsumuro K, Katsuma H, Yamaguchi H, Magata Y, Ohmomo Y - Ann Nucl Med (2013)

Bottom Line: Six quinazoline derivatives were designed and synthesized, and among these, 6a-d were found to have relatively high EGFR-TK inhibitory potency.In contrast, [(125)I]PYK was rapidly cleared from peripheral tissues, resulting in a high tumor-to-tissue ratio 24 h after injection.Moreover, the EGFR-TK selectivity of [(125)I]PYK was confirmed by pretreatment experiments with specific EGFR-TK inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Osaka, Takatsuki 569-1094, Japan.

ABSTRACT

Objective: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) represents an attractive target for tumor diagnosis agents. Previously, radioiodinated 4-(3-iodophenoxy)-6,7-diethoxyquinazoline (PHY) was reported to possess good characteristics as a tumor imaging agent. We have explored the feasibility of developing tumor diagnosis ligands superior to radioiodinated PHY.

Methods: New phenoxyquinazoline derivatives were designed with various side chains introduced to the 6th position of PHY. The IC50 values of the new derivatives to interrupt EGFR-TK phosphorylation were evaluated and compared to well-known EGFR-TK inhibitors. Tumor uptake studies of the new (125)I-labeled derivatives were conducted with A431 tumor-bearing mice. Selectivity and binding characteristics were analyzed by in vitro blocking studies and a binding assay. Furthermore, SPECT/CT scans were performed using A431 tumor-bearing mice.

Results: Six quinazoline derivatives were designed and synthesized, and among these, 6a-d were found to have relatively high EGFR-TK inhibitory potency. In tumor uptake studies, [(125)I]6a ([(125)I]PYK) was found to have the highest tumor uptake and longest retention in tumors. In contrast, [(125)I]PYK was rapidly cleared from peripheral tissues, resulting in a high tumor-to-tissue ratio 24 h after injection. Moreover, the EGFR-TK selectivity of [(125)I]PYK was confirmed by pretreatment experiments with specific EGFR-TK inhibitors. Furthermore, [(125)I]PYK provided clear SPECT images of tumors.

Conclusions: Radioiodinated PYK, one of the newly synthesized quinazoline derivatives, was found to be a desirable ligand for EGFR-TK SPECT imaging. [(125)I]PYK showed high tumor accumulation and selective EGFR-TK binding and also succeeded in delivering high contrast imaging of tumors. These favorable characteristics of [(125)I]PYK suggest that the (123)I-labeled counterpart, [(123)I]PYK, would have great potential for diagnostic SPECT tumor imaging.

Show MeSH

Related in: MedlinePlus

In vivo tumor uptake of 125I labeled phenoxyquinazoline derivatives in A431 tumor-bearing mice. Data represent mean ± SD, n = 3
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3672506&req=5

Fig2: In vivo tumor uptake of 125I labeled phenoxyquinazoline derivatives in A431 tumor-bearing mice. Data represent mean ± SD, n = 3

Mentions: In in vivo tumor uptake studies with A431 tumor-bearing mice (Fig. 2), the accumulation of [125I]6a (4.37 ± 0.65 % ID/g tissue), [125I]6b (1.96 ± 0.10 % ID/g tissue), and [125I]6c (2.73 ± 0.64 % ID/g tissue) in tumors 1 h post injection was higher than that of [125I]PHY (0.56 ± 0.12 % ID/g tissue), while uptake of [125I]6d (0.55 ± 0.12 % ID/g tissue) was similar to [125I]PHY. In addition, [125I]6a was found to have good retention in tumors (1.53 ± 0.15 % ID/g tissue 24 h after injection). On the other hand, [125I]6b, [125I]6c, and [125I]6d showed low retention in tumors 24 h after injection.Fig. 2


A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.

Hirata M, Kanai Y, Naka S, Yoshimoto M, Kagawa S, Matsumuro K, Katsuma H, Yamaguchi H, Magata Y, Ohmomo Y - Ann Nucl Med (2013)

In vivo tumor uptake of 125I labeled phenoxyquinazoline derivatives in A431 tumor-bearing mice. Data represent mean ± SD, n = 3
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3672506&req=5

Fig2: In vivo tumor uptake of 125I labeled phenoxyquinazoline derivatives in A431 tumor-bearing mice. Data represent mean ± SD, n = 3
Mentions: In in vivo tumor uptake studies with A431 tumor-bearing mice (Fig. 2), the accumulation of [125I]6a (4.37 ± 0.65 % ID/g tissue), [125I]6b (1.96 ± 0.10 % ID/g tissue), and [125I]6c (2.73 ± 0.64 % ID/g tissue) in tumors 1 h post injection was higher than that of [125I]PHY (0.56 ± 0.12 % ID/g tissue), while uptake of [125I]6d (0.55 ± 0.12 % ID/g tissue) was similar to [125I]PHY. In addition, [125I]6a was found to have good retention in tumors (1.53 ± 0.15 % ID/g tissue 24 h after injection). On the other hand, [125I]6b, [125I]6c, and [125I]6d showed low retention in tumors 24 h after injection.Fig. 2

Bottom Line: Six quinazoline derivatives were designed and synthesized, and among these, 6a-d were found to have relatively high EGFR-TK inhibitory potency.In contrast, [(125)I]PYK was rapidly cleared from peripheral tissues, resulting in a high tumor-to-tissue ratio 24 h after injection.Moreover, the EGFR-TK selectivity of [(125)I]PYK was confirmed by pretreatment experiments with specific EGFR-TK inhibitors.

View Article: PubMed Central - PubMed

Affiliation: Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Osaka, Takatsuki 569-1094, Japan.

ABSTRACT

Objective: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) represents an attractive target for tumor diagnosis agents. Previously, radioiodinated 4-(3-iodophenoxy)-6,7-diethoxyquinazoline (PHY) was reported to possess good characteristics as a tumor imaging agent. We have explored the feasibility of developing tumor diagnosis ligands superior to radioiodinated PHY.

Methods: New phenoxyquinazoline derivatives were designed with various side chains introduced to the 6th position of PHY. The IC50 values of the new derivatives to interrupt EGFR-TK phosphorylation were evaluated and compared to well-known EGFR-TK inhibitors. Tumor uptake studies of the new (125)I-labeled derivatives were conducted with A431 tumor-bearing mice. Selectivity and binding characteristics were analyzed by in vitro blocking studies and a binding assay. Furthermore, SPECT/CT scans were performed using A431 tumor-bearing mice.

Results: Six quinazoline derivatives were designed and synthesized, and among these, 6a-d were found to have relatively high EGFR-TK inhibitory potency. In tumor uptake studies, [(125)I]6a ([(125)I]PYK) was found to have the highest tumor uptake and longest retention in tumors. In contrast, [(125)I]PYK was rapidly cleared from peripheral tissues, resulting in a high tumor-to-tissue ratio 24 h after injection. Moreover, the EGFR-TK selectivity of [(125)I]PYK was confirmed by pretreatment experiments with specific EGFR-TK inhibitors. Furthermore, [(125)I]PYK provided clear SPECT images of tumors.

Conclusions: Radioiodinated PYK, one of the newly synthesized quinazoline derivatives, was found to be a desirable ligand for EGFR-TK SPECT imaging. [(125)I]PYK showed high tumor accumulation and selective EGFR-TK binding and also succeeded in delivering high contrast imaging of tumors. These favorable characteristics of [(125)I]PYK suggest that the (123)I-labeled counterpart, [(123)I]PYK, would have great potential for diagnostic SPECT tumor imaging.

Show MeSH
Related in: MedlinePlus